Synergen
Executive Summary
Reacquires rights to interleukin-1 receptor antagonist (IL-1ra) from Hoffmann-La Roche. Product is in preclinicals for autoimmune and inflammatory diseases, including rheumatoid arthritis. Worldwide rights to IL-1ra revert to Synergen. Other terms of the agreement were not disclosed. The Boulder, Colorado-based biotech firm and Roche entered into a collaborative effort on the product in May 1989. Synergen, which has approximately $50 mil. in cash on hand, said termination of the agreement would not affect the development of IL-1ra or its other projects, even though Roche's payments accounted for 64% of contract R&D revenues in 1989 and 61% during the first quarter of 1990. The company still expects to being human clinicals on IL-1ra "later this year." Roche's decision followed a reprioritization of its pipeline, according to Synergen.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.